28 May 2025 | 4:57AM EDT Sarepta Therapeutics Inc. (SRPT): Elevidys' full approval is likely intact per CBER Director's commentary We recently hosted a meeting with newly-appointed FDA CBER Director Dr. Vinay Prasad where, in our view, his commentary was supportive of regulatory flexibility balanced with clinical rigor and upholding decisions made by prior CBER leadership (outside of COVID-19). Thus, as it relates to Elevidys in Duchenne muscular dystrophy, our takeaway, inclusive of his prior commentary in ...